This article is more than 5 years old. Information may no longer be current.

Medacta International receives FDA clearance for anterior hybrid interbody fusion device

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Medacta International announced it has received FDA clearance of the MectaLIF Anterior Hybrid Interbody Fusion Device, which will be included in the MectaLIF Cage product suite.

According to a company press release, the MectaLIF System aims to provide enhanced in situ stability, restoration of the native disc space height and lordosis, and long-term maintenance of the spinal balance. The MectaLIF Anterior Hybrid Interbody Fusion Device is the fourth configuration in the MectaLIF product line, which also includes three footprints, two materials and hyperlordotic 20° cage options. The release noted the hybrid configuration will add stability, while the low-profile construct offers a flush caudal and long cranial profile in conjunction with low angle, diverging screws to help with difficult, tilted anatomies.

“The addition of the hybrid makes MectaLIF even more versatile,” S. Raymond Golish, MD, PhD, medical director of the Spine Division at Medacta, said in the release. “We offer surgeons a wide variety of implants tailored to surgeon technique and patient anatomy to optimize outcomes.”

Reference:

www.medacta.com/